ERT's Innovation Lab Opens Today
Through collaboration with leading technology providers, pharmaceutical researchers, and ERT scientists, the Lab is developing and testing diverse technologies for use in clinical research.
ERT, a provider of cloud platform solutions provider for patient-centric data collection and intelligence solutions, has opened its state-of-the-art Innovation Lab, located in ERT’s Boston facility.
ERT’s Innovation Lab is dedicated to creating new and efficient ways for pharmaceutical researchers to safely explore technological concepts with eClinical experts. Through collaboration with leading technology providers, pharmaceutical researchers, and ERT scientists, the Lab is developing and testing diverse technologies for use in clinical research, including new solutions for leveraging wearables, wireless medical devices within clinical trials.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
